Interactions between proteasome and cyclin-dependent kinase inhibitors have been examined in human leukemia cells in relation to induction of apoptosis. Simultaneous exposure (24 h) of U937 myelomonocytic leukemia cells to 100 nm flavopiridol and 300 nm MG-132 resulted in a marked increase in mitochondrial injury (cytochrome c, Smac/DIABLO release, loss of DW m ), caspase activation, and synergistic induction of cell death, accompanied by a marked decrease in clonogenic potential. Similar effects were observed with other proteasome inhibitors (e.g., Bortezomib (VELCADEt bortezomib or injection), lactacystin, LLnL) and cyclin-dependent kinase inhibitors (e.g., roscovitine), as well as other leukemia cell types (e.g., HL-60, Jurkat, Raji). In U937 cells, synergistic interactions between MG-132 and flavopiridol were associated with multiple perturbations in expression/ activation of signaling-and survival-related proteins, including downregulation of XIAP and Mcl-1, activation of JNK and p34 cdc2 , and diminished expression of p21 CIP1 . The lethal effects of MG-132/flavopiridol were not reduced in leukemic cells ectopically expressing Bcl-2, but were partially attenuated in cells ectopically expressing dominant-negative caspase-8 or CrmA. Flavopiridol/ proteasome inhibitor-mediated lethality was also significantly diminished by agents and siRNA blocking JNK activation. Lastly, coadministration of MG-132 with flavopiridol resulted in diminished DNA binding of NFjB. Notably, pharmacologic interruption of the NF-jB pathway (e.g., by BAY 11-7082, PDTC, or SN-50) or molecular dysregulation of NF-jB (i.e., in cells ectopically expressing an IjBa super-repressor) mimicked the actions of proteasome inhibitors in promoting flavopiridol-induced mitochondrial injury, JNK activation, and apoptosis. Together, these findings indicate that proteasome inhibitors strikingly lower the apoptotic threshold of leukemic cells exposed to pharmacologic CDK inhibitors, and suggest that interruption of the NF-jB cytoprotective pathway and JNK activation both play key roles in this phenomenon. They also raise the possibility that combining proteasome and CDK inhibitors could represent a novel antileukemic strategy.
Introduction
The ubiquitin-proteasomal system represents the major nonlysosomal pathway through which intracellular proteins are degraded in eukaryotic cells (Voges et al., 1999) . In an initial recognition step, proteins become attached to ubiquitin molecules, permitting them to be recognized by the 26S proteasome, transferred to a 20S proteolytic chamber, and degraded by proteolysis (Glickman and Ciechanover, 2002) . This proteasomal degradation system is involved in homeostatic control of diverse cellular proteins, including those involved in cell survival, signaling, and in particular, cell cycle regulation (Adams, 2002a) . Recently, evidence has emerged indicating that the ubiquitin-proteasomal pathway is intimately involved in the control of apoptosis (Jesenberger and Jentsch, 2002) . Although the mechanism underlying this phenomenon has not yet been fully elucidated, involvement of the IKK/NF-kB axis represents one of the leading candidates (Goldberg and Rock, 2002) . Of late, interest in proteasome inhibitors as antineoplastic agents has been sparked by observations that these compounds are very effective inducers of apoptosis in malignant human hematopoietic cells, including multiple myeloma and myeloid leukemia (Hideshima et al., 2001; Soligo et al., 2001; Guzman et al., 2002) . Significantly, proteasome inhibitors have been shown to induce apoptosis in human leukemia cells that ectopically express the antiapoptotic protein Bcl-2 . One such agent, the synthetic dipeptide boronic acid bortezomib has been identified as a potent inducer of cell death in several human tumor cell types (Teicher et al., 1999; Adams, 2002b) . Based upon these and other findings, bortezomib is currently undergoing clinical evaluation in humans, and initial results in patients with multiple myeloma appear promising (Orlowski et al., 2002) .
Since cell cycle dysregulation is a hallmark of neoplastic cells (Sandal, 2002) , intense efforts have been directed at developing small molecule inhibitors of cell cycle progression (Senderowicz, 2000) . A prototypical example of this class of agents is flavopiridol (NSC 649890, , a rohitukine alkaloid that inhibits cyclin-dependent kinases (CDKs) 1, 2, 4/6, 7, and 9 (Senderowicz, 1999; Chao and Price, 2001) , and in some cell types, downregulates expression of cyclin D 1 (Carlson et al., 1999) . In addition to its ability to induce cell cycle arrest (Carlson et al., 1996) , flavopiridol also triggers apoptosis in tumor cells, particularly those of hematopoietic origin (Parker et al., 1998) . In lung cancer cells, flavopiridol-induced apoptosis proceeds, at least in part, through activation of the receptor-related, extrinsic apoptotic pathway (Achenbach et al., 2000) . However, in human leukemia cells, flavopiridol-mediated cell death has been related to induction of mitochondrial injury, that is, loss of mitochondrial membrane potential (DC m ) and release of cytochrome c into the cytosol . Several clinical trials involving flavopiridol have been completed, and have established the feasibility of achieving plasma flavopiridol concentrations 4300 nm (Thomas et al., 2002) , which exceed levels necessary to induce apoptosis in human leukemia cells (Karp et al., 2003) . In addition, preclinical data demonstrating synergism between flavopiridol and cytotoxic agents such as paclitaxel (Motwani et al., 1999) , as well as certain differentiation-inducing compounds (e.g., phorbol 12-myristate 13-acetate; sodium butyrate) (Cartee et al., 2001; Rosato et al., 2002) , provide the impetus for developing new therapeutic strategies in which flavopiridol might be combined with either established or more novel antineoplastic drugs.
The ability of proteasome inhibitors to induce apoptosis in tumor cells (Teicher et al., 1999; Adams, 2002b) has prompted efforts to determine whether they might also lower the apoptotic threshold for standard cytotoxic drugs. In this regard, synergistic antileukemic interactions between proteasome inhibitors and various conventional cytotoxic drugs have been reported . However, little information is currently available concerning interactions between proteasome inhibitors and other novel agents that interrupt signal transduction and cell cycle regulatory pathways. For example, the possibility exists that combined exposure of neoplastic cells to such agents may disrupt multiple cytoprotective signaling pathways, thereby producing a particularly potent apoptotic stimulus. In this context, previous studies have demonstrated synergistic interactions between the proteasome inhibitor lactacystin and the protein kinase C (PKC) activator and downregulator bryostatin 1 in human myeloid leukemia cells (Vrana and Grant, 2001 ). To investigate this possibility further, we have examined interactions between proteasome inhibitors and flavopiridol in a variety of leukemia cell types. Here we report that combined exposure to low, minimally toxic concentrations of proteasome inhibitors in combination with a pharmacologically achievable concentration of flavopiridol (e.g., 100 nm) results in synergistic induction of mitochondrial damage, caspase activation, and apoptosis in multiple human leukemia cell types. Moreover, these events are associated with activation of the stress-related c-Jun N-terminal kinase (JNK) pathway, and are mimicked by pharmacologic and molecular disruption of the cytoprotective NF-kB cascade. Together, these findings suggest that the NF-kB axis plays a key role in protecting leukemic cells from the lethal consequences of cell cycle dysregulation, and raise the possibility that combination of clinically relevant proteasome inhibitors with CDK inhibitors such as flavopiridol may represent a novel therapeutic strategy in leukemia.
Results
Combined exposure of human leukemia cells (U937) to flavopiridol and diverse proteasome inhibitors dramatically increases mitochondrial injury, apoptosis, and loss of clonogenic survival
To assess interactions between these agents, U937 cells were exposed for 24 h to a minimally toxic concentration of flavopiridol (100 nm) in conjunction with MG-132 (300 nm), lactacystin (500 nm), or LLnL (5 mm), after which apoptosis and loss of DC m were assessed (Figure 1) . Treatment of cells with p100 nm flavopiridol or p300 nm MG-132 alone was ineffective in inducing apoptosis, whereas significant toxicity was noted with higher concentrations (i.e., 200-300 nm flavopiridol or 600 nm MG-132 (Figure 1a) ). As shown in Figure 1b , coadministration of 100 nm flavopiridol with marginally cytotoxic concentrations of each of the proteasome inhibitors resulted in a dramatic increase in the percentage of apoptotic cells. Parallel results were obtained when Annexin V/PI analysis was employed (data not shown). A marked increase in mitochondrial injury, reflected by loss of DC m , was also observed in cells treated with the combination of flavopiridol and proteasome inhibitors (Figure 1c ). Since the extent of apoptosis may not correlate with loss of leukemic selfrenewal capacity, clonogenic assays were performed. Coadministration of flavopiridol and MG-132, which individually exerted relatively modest inhibitory effects, reduced clonogenicity to B10% of control values (Figure 1d ). Together, these findings indicate that coadministration of flavopiridol with several proteasome inhibitors in human leukemia cells results in a marked increase in mitochondrial injury, apoptosis, and loss of clonogenic survival.
Combined treatment with flavopiridol and MG-132 results in a marked increase in apoptosis in primary human blasts To establish whether these findings could be extended to primary leukemic cells or were restricted to continuously Flavopiridol/proteasome inhibitor-induced apoptosis Y Dai et al cultured cell lines, parallel studies were performed in leukemic blasts obtained from the peripheral blood of two patients with acute myelogenous leukemia (FAB subtype M2; Figure 2a and b). Exposure of blasts to 300 nm MG-132 for 24 h exerted minimal toxicity in either sample, whereas flavopiridol alone was modestly (patient #1; 100 nm) or minimally toxic (patient #2; 75 nm). However, in both cases, combined treatment resulted in a marked increase in apoptosis (i.e., in 60-90% of cells). These findings indicate that combined exposure to flavopiridol and proteasome inhibitors results in a marked increase in cell death in at least some primary AML samples.
Coadministration of the clinically relevant proteasome inhibitor bortezomib with the CDK inhibitor roscovitine synergistically induces apoptosis in U937 cells
To determine whether these observations could be extended to a clinically relevant proteasome inhibitor, as well as other CDK inhibitors, U937 cells were exposed to 5 nm bortezomib712 mm roscovitine for 24 h, after which the percentage of Annexin V/PI þ cells was determined by flow cytometry. Whereas roscovitine and bortezomib administered alone induced B20 and 18% apoptosis, respectively, combined treatment resulted in B70% apoptotic cells (Figure 2c ). Median dose-effect analysis of apoptosis induction over several bortezomib and roscovitine concentrations administered at a fixed ratio (1 : 2000) yielded Combination Index (CI) values o1.0 (Figure 2d ), corresponding to synergistic interactions. These observations indicate that synergistic induction of apoptosis by proteasome and CDK inhibitors in human leukemia cells can be extended to the clinically relevant agent bortezomib, as well as CDK inhibitors other than flavopiridol.
Combined treatment of human leukemia cells (U937) with flavopiridol and proteasome inhibitors results in release of proapoptotic mitochondrial proteins and caspase activation
Western blot analysis of cell lysates obtained from cells exposed to 100 nm flavopiridol7300 nm MG-132 for 24 h revealed a striking increase in release of the proapoptotic mitochondrial proteins cytochrome c and Smac/DIABLO into the cytosolic S-100 fraction, following combined treatment with both agents (Figure 3a) . These events were accompanied by a Figure 1 (a) U937 cells were incubated for 24 h in the presence of the indicated concentration of flavopiridol (FP; nm) or MG-132 (MG; nm), after which the percentage of cells exhibiting apoptotic morphology was determined by evaluating Wright-Giemsa-stained cytospin preparations. (b) U937 cells were incubated for 24 h in the presence of 100 nm FP 7300 nm MG, 500 nm lactacystin (LC), or 5 mm LLnL, respectively, after which the percentage of cells exhibiting apoptotic morphology was determined as above. (c) U937 cells were treated as above for 24 h, after which the percentage of cells exhibiting reduced mitochondrial membrane potential (DC m ) was determined by monitoring DiOC 6 uptake. (d) U937 cells were treated with 100 nm FP 7300 nm MG for 24 h, after which cells were washed free of drug and plated in soft agar as described in Materials and methods. After 12 days incubation, colonies were scored, and colony formation for each condition expressed relative to untreated control cells. , and XIAP Effects of these agents on activation of MAP kinase pathways were examined next. As shown in Figure 5a , individual treatment of cells with flavopiridol (100 nm) or MG-132 (300 nm) had little effect on the expression of phospho-JNK, whereas combined treatment resulted in a striking increase in JNK phosphorylation. In addition, an increase in JNK phosphorylation was also observed in U937 cells treated with more toxic concentrations of MG-132 (500 nm) or flavopiridol (200 nm) alone, but not to the extent of that observed in cells exposed to agents administered in combination (data not shown). Enhanced JNK activation in flavopiridol/MG-132-treated cells was confirmed by a JNK kinase assay, demonstrating a marked increase in phosphorylation of a GST-cJun protein. Moreover, the increase in JNK activation was noted in U937 cells exposed to flavopiridol and lactacystin (500 nm) (Figure 5c ), as well as in HL-60, Raji, and Jurkat cells exposed to flavopiridol þ MG-132 ( Figure 5d ). In contrast, the agents administered individually or in combination had little effect on expression of phospho-ERK or -p38 MAPK. Together, Figure 3 U937 cells were treated for 24 h with 100 nm flavopiridol7300 nm MG-132 (a), or 7500 nm lactacystin (b), after which cells were lysed and subjected to Western blot using the indicated antibodies. CF ¼ cleavage fragment. Alternatively, cytosolic fractions were obtained, and expression of cytochrome c and Smac/ DIABLO were monitored by Western blot. Each lane was loaded with 25 mg of protein; blots were stripped and reprobed with antibodies to tubulin or actin to ensure equal loading and transfer. Two additional studies yielded equivalent results
Flavopiridol/proteasome inhibitor-induced apoptosis
Y Dai et al regard, we have previously reported that flavopiridol represses p21 CIP1 expression at the transcriptional level . Levels of p27 KIP1 markedly declined in flavopiridol/MG-132-treated cells (Figure 5b ), an event that was blocked by Boc-D-fmk (data not shown). Little change was noted in the expression of Bcl-2, Bclx L , and Bax in cells treated with flavopiridol7MG-132, although a Bax cleavage product was noted in cells exposed to both agents. Interestingly, MG-132 alone resulted in upregulation of the antiapoptotic protein Mcl-1, whereas this effect was blocked in cells coexposed to flavopiridol. Analogous to the case of p21 CIP1 , Mcl-1 downregulation was also not attenuated by Boc-D-fmk (data not shown), suggesting transcriptional repression by flavopiridol, as recently reported (Gojo et al., 2002) . Similar results were noted in cells treated with flavopiridol þ lactacystin (500 nm; Figure 5c ). Lastly, XIAP levels were reduced in cells exposed to the combination of flavopiridol and MG-132 or lactacystin. Thus, coadministration of flavopiridol and MG-132 in U937 cells resulted in multiple perturbations in survival-, cell cycle-, and stress-related pathways.
Activation of JNK plays a functional role in flavopiridol/MG-132-mediated apoptosis
To determine if enhanced JNK activation played a functional role in flavopiridol/proteasome inhibitormediated apoptosis, U937 cells were exposed to 100 nm flavopiridol þ either 300 nm MG-132 or 500 nm lactacystin in the presence of the JNK inhibitory peptide D-JNKI1 (1 mm) or an inactive control (D-TAT), after which loss of DC m or apoptosis was assessed (Figure 6a ). D-JNKI1 is a bioactive cell-permeable peptide consisting of the 20-amino-acid inhibitory domain of the isletbrain (IB) protein, a potent JNK inhibitor, linked to a 10-amino-acid HIV-TAT sequence that rapidly translocates into cells (Bonny et al., 2001) . Coadministration of D-JNKI1 markedly inhibited loss of DC m and apoptosis in flavopiridol/proteasome inhibitor-treated cells (Figure 6a ; Po0.01 in each case), whereas the control peptide exerted no effect. Western blot analysis revealed that D-JNKI1, but not D-TAT, blocked flavopiridol/ proteasome inhibitor-induced JNK activation and PARP cleavage (Figure 6b ). In addition, reduction in expression of total JNK1 and phospho-JNK1 by siRNA
Figure 5 U937 cells were treated with 100 nm flavopiridol7300 nm MG-132 for 24 h, after which expression of phosphorylated MAP kinases (e.g. SAPK/JNK, ERK, and p38) (a), cell cycle regulators (e.g. p34 cdc2 , p21 CIP/WAF1 , p27 KIP1 ), and apoptotic regulators (e.g. Bcl-2, Bcl-x L , Bax, XIAP, and Mcl-1) (b) were monitored by Western blot. Alternatively, cell lysates were subjected to SAPK/JNK kinase assay. SAPK/JNK activity was reflected by phosphorylated GST-c-Jun (a, bottom panel). Similarly, U937 cells were treated with 100 nm flavopiridol7500 nm lactacystin for 24 h (c), after which expression of indicated protein was analysed by Western blot. Phosphorylation of SAPK/JNK was also monitored in HL-60, Jurkat, and Raji cells after treatment with 150 nm flavopiridol þ 500 nm MG-132 for 24 h (d). Each lane was loaded with 25 mg of protein; blots were stripped and reprobed with antibodies to tubulin or actin to ensure equal loading and transfer. Results are representative of three separate experiments The results of previous studies have suggested that flavopiridol and proteasome inhibitors induce apoptosis regardless of Bcl-2 status Achenbach et al., 2000) . To determine whether Bcl-2 could protect cells from the lethal effects of the flavopiridol/proteasome inhibitor regimen, a transfectant U937 cell line ectopically expressing Bcl-2 was employed (Figure 7a ). U937/Bcl-2 cells approximately exhibit a fourfold increase in Bcl-2 protein compared to empty vector controls (pCEP; Figure 7a , inset). As shown in Figure 7 , U937/Bcl-2 cells were significantly less sensitive than controls to loss of DC m (Figure 7a (Figure 8c ). Together, these observations indicate that flavopiridol/proteasome inhibitormediated antileukemic effects proceed, at least in part, through a caspase-8-dependent process.
Flavopiridol/proteasome inhibitor regimens inhibit NF-kB DNA binding
Proteasome inhibitors are known to interfere with the NF-kB pathway by blocking degradation of IkB (Tan and Waldmann, 2002) . To determine what effect combined exposure of flavopiridol and proteasome inhibitors might have on DNA binding of NF-kB, an electrophoretic mobility shift assay (EMSA) was performed ( Figure 9a ). The specificity of NF-kB was evaluated by competition, and by supershift analysis (upper panel) on nuclear proteins prepared from untreated U937 cells. The unlabeled DNA probe as well as specific anti-p50 and anti-p65 antibodies markedly reduced the band corresponding to the NFkB-containing complex. In addition, supershifted bands were observed with the p50 antibody. Exposure of U937 cells to 100 nm flavopiridol alone reduced NF-kB DNAbinding activity, as did 300 nm MG-132. However, combined treatment resulted in a further decline in 
Leukemic cells ectopically expressing an IkBa 'super-repressor' display a marked increase in sensitivity to flavopiridol
To gain insights into the functional significance of interference with the NF-kB pathway in flavopiridolmediated lethality, U937 cell lines ectopically expressing an IkBa 'super-repressor' mutant protein were employed (Ryan et al., 2000) . This protein is unable to undergo phosphorylation on residues 32 and 36 as both serines 32 and 36 have been substituted with alanine, resulting in interference with proteasomal degradation. Consequently, the mutant IkBa protein remains in the cytoplasm, where it binds to NF-kB and prevents nuclear translocation (Alkalay et al., 1995) . As illustrated by results of EMSA analysis (Figure 9b) Figure 9c , when administered at concentrations of 50-125 nm, flavopiridol induced significantly more apoptosis in the two mutant cell lines compared to wild-type controls. Essentially, parallel results were obtained when loss of DC m was monitored (data not shown). Consistent with these results, 50 nm flavopiridol was clearly more effective in triggering release of cytochrome c and Smac/DIABLO into the cytoplasm as well as PARP cleavage in mutant U937 cells (2H6) than in empty vector controls (pcDNA 3.1) (Figure 9d) . Levels of XIAP, a downstream target of NF-kB (Stehlik et al., 1998) , were also diminished in flavopiridol-treated 2H6 cells, whereas Mcl-1 expression was reduced in both mutant U937 cells (2H6) and empty vector controls (pcDNA 3.1). Lastly, cells expressing mutant IkBa protein (2H6) displayed enhanced JNK activation in the presence or absence of flavopiridol compared to empty vector controls (Figure 9d ). Together, these findings suggest that NF-kB plays a significant functional role in protecting leukemic cells from flavopiridolmediated mitochondrial injury and apoptosis, and supports the notion that diminished NF-kB activity in flavopiridol/MG-132-treated cells contributes to the enhanced lethality of this drug combination.
Pharmacologic interruption of the NF-kB pathway sensitizes leukemic cells to flavopiridol-mediated lethality
Parallel results were obtained when pharmacologic inhibitors of the NF-kB pathway were utilized. For example, when combined with a subtoxic concentration was employed, whereas a control peptide (SN50M) had no effect (Figure 10b ). Consistent with these findings, cotreatment of cells with Bay 11-8072 þ flavopiridol resulted in a striking increase in cytochrome c and Smac/DIABLO release and PARP degradation, as well as enhanced JNK activation, XIAP and Mcl-1 downregulation (Figure 10c ). Taken together with the preceding results, these findings indicate that disruption of the NF-kB cytoprotective pathway markedly potentiates flavopiridol-mediated lethality. They are also compatible with the notion that interference with NF-kB function by proteasome inhibitors contributes to synergistic interactions between these agents and flavopiridol.
Discussion
The mechanism by which proteasome inhibitors, which regulate the disposition of diverse signaling and cell cycle regulatory proteins, kill neoplastic cells is not known with certainty, but may involve accumulation of proapoptotic Bcl-2 family members (e.g., Bax) (Li and Dou, 2000) , activation of stress-related proteins (e.g., SAPK) (Meriin et al., 1998) , or disabling of cytoprotective pathways (e.g., NF-kB) (Porcile et al., 2002) . Proteasome inhibitors have also been shown to enhance the antitumor activity of conventional cytotoxic agents, including etoposide and doxorubicin (Ogiso et al., 2000) . Currently, however, the concept of combining proteasome inhibitors with more novel agents that act at the level of signal transduction or cell cycle regulation has been little explored. Recently, attention has focused on Figure 9 (a) U937 cells were left untreated or treated with 300 nm MG-132 (upper left panel) for 24 h or 10 ng/ml TNFa for 15 h (lower panel) in the presence or absence of 100 nm flavopiridol, after which nuclear extracts were prepared and subjected to EMSA, as described in Materials and methods. Supershift analysis was performed using specific anti-p50 and anti-p65 antibodies to determine the identity of NF-kB-containing complexes (upper right panel). For C þ C 0 , 100-fold excess of unlabeled NF-kB oligonucleotides was coincubated for 10 min with the nuclear extract obtained from untreated cells prior to addition of labeled NF-kB oligonucleotides. Two additional studies yielded equivalent results. (b) U937 cells were stably transfected with IkBa mutant (Ser32, 36/Ala) or an empty vector (pcDNA3.1). Two U937 cell clones stably expressing IkBa mutant (2H6, 2C8), as well as empty vector controls (pCDNA 3.1) were treated with 5 ng/ml TNFa for 5 min and then subjected to EMSA as above. (Senderowicz, 2000) . Aside from their antiproliferative actions (Carlson et al., 1996) , CDK inhibitors also induce apoptosis in malignant cells through mechanisms yet to be elucidated (Sedlacek, 2001 ). The present results suggest that in human leukemia cells, the lethal actions of such agents may be dramatically enhanced by one or more perturbations induced by agents that disrupt proteasome function.
Our findings also indicate that the ability of proteasome inhibitors to interact synergistically with flavopiridol and other CDK inhibitors can be extended to a variety of human leukemic cell types. Moreover, the lethality of this combination is characterized by a marked increase in mitochondrial injury, particularly release of proapoptotic mitochondrial proteins (e.g., cytochrome c and Smac/DIABLO), which culminates in caspase activation and apoptosis. It is noteworthy that ectopic expression of Bcl-2, which attenuates mitochondrial injury by interfering with the proapoptotic actions of BH3-only domain members of the Bcl-2 family (Cheng et al., 2001) , failed to protect leukemic cells from flavopiridol/proteasome inhibitor-mediated lethality. Such findings are consistent with earlier reports suggesting that the lethal effects of proteasome inhibitors as well as flavopiridol (Achenbach et al., 2000) may operate through Bcl-2-independent mechanisms. The observation that ectopic expression of DN-caspase-8 or CrmA attenuated the lethality of this regimen is consistent with results of previous studies indicating that caspase-8 activation can amplify the cytotoxicity of agents that act primarily by triggering mitochondrial damage (Sun et al., 1999) . In view of evidence that a discordance may exist between apoptosis and reduction in clonogenic survival (Ao et al., 2001) , it is important to note that coadministration of flavopiridol and proteasome inhibitors resulted in a marked reduction in clonogenicity. This finding indicates that self-renewing leukemic cells are highly susceptible to the lethal effects of this regimen.
Several lines of evidence suggest that potentiation of flavopiridol-mediated lethality by proteasome inhibitors involves, at least in part, disruption of the NF-kB pathway. First, coadministration of MG-132 with flavopiridol was associated with a further diminution in NF-kB DNA binding. Second, disruption of the NFkB by either molecular means (e.g., transfection of cells with an IkBa super-repressor) or by pharmacologic agents (e.g., Bay 11-7082, PDTC, SN-50) mimicked the ability of MG-132 to potentiate flavopiridol lethality. Such findings are analogous to those of earlier reports indicating that disabling the NF-kB pathway (i.e., by enforced expression of the IkBa super-repressor) sensitizes them to the lethal actions of conventional cytotoxic drugs (Arlt et al., 2001) . They are also in accord with a recent report indicating that flavopiridol diminishes NF-kB activation in A549 lung cancer cells exposed to TNFa (Kim et al., 2003) . Although the mechanism by which flavopiridol triggers mitochondrial injury in leukemia cells is uncertain, based upon the Figure 10 (a) U937 cells were treated for 24 h with 75 nm flavopiridol73 mm Bay 11-7082 or 7250 nm PDTC, after which the percentage of cells exhibiting apoptotic morphology was determined. (b) U937 cells were treated for 24 h with 75 nm flavopiridol in the presence of either NF-kB-inhibitory peptide (SN50, 150 mg/ml) or its inactive control (SN50M, 150 mg/ml), after which the percentage of apoptotic cells was determined as above. (c) U937 cells were treated with flavopiridol7Bay 11-7082 as above, after which whole-cell lysates were subjected to Western blot. In addition, cytosolic fractions were prepared to monitor release of mitochondrial cytochrome c and smac/DIABLO. Two additional studies yielded equivalent results. Each lane was loaded with 25 mg of protein; blots were stripped and reprobed with antibodies to actin to ensure equal loading and transfer. For (a, b) , the values represent the means7s.d. for three separate experiments performed in triplicate Flavopiridol/proteasome inhibitor-induced apoptosis Y Dai et al present results, it is likely that the NF-kB pathway plays a significant functional role in attenuating this process. Thus, it is tempting to speculate that proteasome inhibitors, by promoting cytosolic accumulation of IkB and interfering with NF-kB function Hipp et al., 2002) , lower the threshold for flavopiridol-mediated mitochondrial damage. However, given the pleiotropic consequences of proteasome inhibitor actions , the possibility that more than one mechanism may be involved in synergistic interactions with flavopiridol cannot be excluded. NF-kB has been implicated in the regulation of several antiapoptotic proteins, including Bcl-x L (Dong et al., 2002) and XIAP, an inhibitor of apoptosis protein that directly antagonizes the activation of effector caspases such as caspase-3 (Suzuki et al., 2001) . In contrast, Bcl-x L acts by preventing mitochondrial injury (e.g., the release of cytochrome c) (Yamaguchi and Wang, 2002) . In this context, flavopiridol has been shown to reduce expression of both XIAP and Bcl-x L in human leukemia cells (Kitada et al., 2000; Wittmann et al., 2003) , events that might reflect inhibition of the CDK9/cyclin T transcription complex (Chao and Price, 2001) . Although Bcl-x L expression was unperturbed in flavopiridol/proteasome inhibitor-treated cells, XIAP levels were significantly diminished, potentially contributing to enhanced cell death. In addition, exposure of U937 cells to proteasome inhibitors resulted in accumulation of the antiapoptotic protein Mcl-1, which has recently been shown to play an important role in malignant hematopoietic cell survival (Zhou et al., 1998) . This finding raises the possibility that increased expression of Mcl-1 may serve to limit the lethality of proteasome inhibitors. As a corollary, flavopiridol, which has been shown to diminish Mcl-1 expression (Gojo et al., 2002) , may thereby potentiate proteasome inhibitor lethality.
Enhanced lethality of the flavopiridol/proteasome inhibitor regimen was also associated with marked activation of JNK, a stress-related kinase known to be involved in the induction of mitochondrial injury and apoptosis (Xia et al., 1995) . Significantly, pharmacologic JNK inhibitors as well as siRNA directed against JNK attenuated flavopiridol/proteasome inhibitor-induced apoptosis; conversely, the JNK activator anisomycin exerted the opposite effect. Such findings are consistent with previous reports linking proteasome inhibitor-mediated lethality with enhanced activation of stress-activated protein kinases (Meriin et al., 1998; Hideshima et al., 2003) . It is worth noting that flavopiridol-mediated JNK activation was potentiated by the pharmacologic NF-kB inhibitor Bay 11-7082, as well as in cells ectopically expressing the IkB super-repressor, indicating that induction of JNK lies downstream of NF-kB inactivation (Arsura et al., 2003) . These observations are in accord with those of recent reports demonstrating that NF-kB opposed TNFamediated JNK activation through a process partly dependent upon XIAP or Gadd45b (De Smaele et al., 2001; Tang et al., 2001 ).
In summary, the present findings indicate that proteasome inhibitors interact in a highly synergistic manner with pharmacologic CDK inhibitors to induce mitochondrial injury, caspase activation, and apoptosis in diverse human leukemia cell types. Potentiation of CDK inhibitor lethality is associated with disruption of the NF-kB pathway, is mimicked by molecular and pharmacologic NF-kB inhibitors, and depends, at least in part, upon activation of the stressrelated MAP kinase JNK. Furthermore, the enhanced lethality of this regimen is associated with diminished expression of the antiapoptotic proteins XIAP and Mcl-1. A hypothetical model summarizing these interactions is illustrated in Figure 11 . In this model, proteasome inhibitors promote flavopiridol lethality by disabling the NF-kB pathway and promoting JNK activation. These effects can be mimicked at the levels of IkB (IkBa mutant) and NF-kB (Bay 11-7082, SN50), or blocked by disruption of the JNK pathway (i.e., by D-JNK inhibitor 1 or JNK1 siRNA). Flavopiridol may also promote JNK activation by inhibiting NF-kB and downregulating XIAP, and oppose the putative cytoprotective effects of proteasome inhibitor-mediated Mcl-1 accumulation. In view of the recent introduction of both proteasome inhibitors such as bortezomib (Adams, 2002b; Orlowski et al., 2002) and CDK inhibitors such as flavopiridol (Senderowicz, 1999; Thomas et al., 2002) into clinical trials in humans, these findings raise the possibility that combined treatment with such agents may represent a novel antileukemic strategy. Accordingly, further attempts to develop this approach are currently underway. 
Materials and methods

Cells and reagents
U937 human histiocytic leukemia, HL-60 acute promyelocytic leukemia, Jurkat acute T-cell leukemia, and Raji Burkitt's lymphoma cells were obtained from ATCC and maintained in 10% FBS-RPMI 1640 medium as previously reported . U937 cells were stably transfected with an IkBa mutant in which both serines 32 and 36 have been mutated to alanine, CrmA, DN-caspase-8 cDNA, or an empty vector (pcDNA3.1), and clones selected with G418 . U937/Bcl-2 and /pCEP4 cells were obtained by stable transfection of cells with Bcl-2 cDNA or an empty vector (pCEP4), after which clones were selected with hygromycin (Tang et al., 2000) . All experiments were performed utilizing logarithmically growing cells (3-5 Â 10 5 cells/ml). Leukemic blasts were obtained with informed consent from the peripheral blood of two patients with acute myelogenous leukemia, FAB subtype M2. These studies have been approved by the Investigational Review Board of Virginia Commonwealth University. Samples, which contained 485% blasts in each case, were separated by centrifugation over Ficoll/ Hypaque (specific gravity 1.077-1.081; Sigma, St Louis, MO, USA) at 400 g at room temperature for 38 min. The interface layer, containing primarily blasts, was extracted using a sterile Pasteur pipette, and resuspended in medium containing 10% FBS. The cells, which exhibited 496% viability by trypan blue exclusion, were treated exactly as continuously cultured cell lines.
The pan-CDK inhibitor flavopiridol was kindly provided by Dr Edward Sausville (Developmental Therapeutics Program/CTEP, NCI). The specific proteasome inhibitor bortezomib (VELCADEt, formerly known as PS-341) was kindly provided by Millenium Pharmaceuticals Inc. (Cambridge, MA, USA). These agents were dissolved in DMSO as a stock solution, stored at À801C. Roscovitine (a CDK inhibitor, Biomol, Plymouth Meeting, PA, USA), MG-132 and LLnL (selective proteasome inhibitors, Biomol), lactacystin (a specific proteasome inhibitor, Alexis, San Diego, CA, USA), Bay 11-7082 (an inhibitor of IkBa phosphorylation, Alexis), anisomycin (a JNK/SAPK activator, Biomol), cycloheximide (a protein synthesis inhibitor, Sigma, St Louis, MO, USA), and VP-16 (etoposide, Sigma) were dissolved in sterile DMSO and stored frozen under light-protected conditions at À201C. Pyrrolidine dithiocarbamic acid (PDTC, an NF-kB inhibitor, Alexis), SN50 (a specific NF-kB-inhibitory peptide, Alexis), and SN50M (control inactive peptide) were dissolved in sterile H 2 O, aliquoted, and stored at À201C. c-Jun N-terminal kinase peptide inhibitor 1 (D-JNKI1, D-stereoisomer) and its control peptide D-TAT were purchased as solution in sterile PBS from Alexis. Recombinant human TNFa (Calbiochem, San Diego, CA, USA) was rehydrated in PBS containing 0.5% BSA, aliquoted, and stored at À801C. In all experiments, the final concentration of DMSO did not exceed 0.1%.
Analysis of apoptosis
The extent of apoptosis was evaluated by assessment of Wright-Giemsa-stained cytospin preparation under light microscopy and scoring the number of cells exhibiting classic morphological features of apoptosis. For each condition, 5-10 randomly selected fields per condition were evaluated, encompassing at least 800 cells. To confirm the results of morphologic analysis, in some cases cells were also evaluated by Annexin V-FITC staining .
Analysis of mitochondrial membrane potential (DC m )
Cells (2 Â 10 5 ) were incubated with 40 nm 3,3-dihexyloxacarbocynine (DiOC 6 , Molecular Probes Inc., Eugene, OR, USA) in PBS at 371C for 20 min, and then analysed by flow cytometry. The percentage of cells exhibiting low level of DiOC 6 uptake, which reflects loss of mitochondrial membrane potential, was determined using a Becton-Dickinson FACScan (Becton-Dickinson, San Jose, CA, USA).
Western blot analysis
Whole-cell pellets were lysed in SDS sample buffer and 25 mg protein for each condition was subjected to Western blot analysis following procedures previously described in detail . Where indicated, the blots were reprobed with antibodies against actin (Transduction Lab., Lexington, KY, USA) or tubulin (Calbiochem) to ensure equal loading and transfer of proteins. The following antibodies were used as primary antibodies: phospho-p44/42 MAP kinase (Thr202/ Tyr204) antibody (Cell Signaling, Beverly, MA, USA), phospho-p38 MAP kinase (Thr180/Tyr182) antibody (Cell Signaling), phospho-JNK (Thr183/Tyr185) antibody (Santa Cruz, Santa Cruz, CA, USA), SAPK/JNK antibody (Cell Signaling), JNK1 antibody (Santa Cruz), JNK2 antibody (Santa Cruz), phospho-cdc2 (Tyr15) Analysis of cytosolic cytochrome c and Smac/DIABLO Cells (2 Â 10 6 ) were washed in PBS and lysed by incubating for 30 s in lysis buffer (75 mm NaCl, 8 mm Na 2 HPO 4 , 1mm NaH 2 PO 4 , 1 mm EDTA, and 350 mg/ml digitonin). The lysates were centrifuged at 12 000 g for 1 min, and the supernatant was collected and added to an equal volume of 2 Â sample buffer. The protein samples were quantified, separated by 15% SDS-PAGE, and subjected to Western blot analysis. Anticytochrome c (Pharmingen) and smac/DIABLO antibody (Upstate Biotechnology, Lake Placid, NY, USA) were used as primary antibodies.
SAPK/JNK kinase assay
A SAPK/JNK Assay Kit (Cell Signaling) was used to monitor the activity of SAPK/JNK kinase as per the manufacturer's instructions. Briefly, 2 Â 10 7 cells were lysed in cell lysis buffer plus 1 mm PMSF by sonication. Protein (250 mg) per condition was incubated with 2 mg of c-Jun fusion protein beads overnight at 41C. The beads were washed twice, and then incubated with 100 mm ATP in kinase buffer at 301C for 30 min. The reaction was terminated by adding 3 Â SDS sample buffer. GST-c-Jun was separated by 15% SDS-PAGE and visualized by Western blot by using phospho-c-Jun (Ser63) antibody (Cell Signaling) as primary antibody.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as described previously (Rahmani et al., 2001) . Double-stranded oligonucleotides corresponding to the NF-kB binding site of Igk promoter 5 0 -AGTTGAGGGGACT TTCCCAGGC-3 0 were obtained from Promega (Madison, WI, USA) and labeled with [g- 32 P]ATP (3000 Ci/mmol, ICN Biomedicals, Irvine, CA, USA) using T4 polynucleotide kinase (Promega) and purified using MicroSpin G-25 column (Amersham Pharmacia, Piscataway, NJ, USA). Nuclear extracts (5 mg) were incubated at 41C for 20 min with 10 5 c.p.m. of labeled oligonucleotide probe in 15 ml of binding buffer (20 mm HEPES, pH 7.9, 5 mm MgCl 2 , 4 mm dithiothreitol, 20% glycerol, 0.1 mm phenylmethylsulfonyl fluoride, 5 mm benzamidine, 2 mm levamisol, 0.1 mg/ml aprotinin, 0.1 mg/ml bestatin, 2 mg poly(dI/dC)). For supershift analysis, nuclear extracts were incubated at 41C for 30 min with specific anti-p50 and anti-p65 antibodies (Santa Cruz Biotechnology) prior to addition of radiolabeled oligonucleotides. The reaction mixtures were then loaded onto 6% native polyacrylamide gels in 0.5 Â TBE (pH 8.0), and electrophoresed for 2 h at 150 V. The gels were dried at 801C and exposed to X-ray film for autoradiography.
RNA interference
U937 cells (2 Â 10 6 ) were transfected with 800 ng JNK1 (MAPK8) annealed dsRNAi oligonucleotide 5 0 -CGUG-GAUUUAUGGUCUGUGTT-3 0 /3 0 -TTGCACCUAAAUAC CAGACAC-5 0 (Orbigen, San Diego, CA, USA). After incubation at 371C for 24 h, cells were treated with drugs as indicated for 24 h, and subjected to analysis of apoptosis (Wright-Giemsa staining and Annexin V-FITC staining) and Western blot as described above.
Clonogenic assay
Colony formation following drug treatment was evaluated using a soft agar cloning assay as described previously . Briefly, cells were washed three times with serumfree RPMI medium. Subsequently, 500 cells/well were suspended in RPMI medium containing 20% FBS and 0.3% agar, and plated in 12-well plates (three wells per condition). After 12 days incubation, colonies, consisting of groups of 450 cells, were scored using an Olympus Model CK inverted microscope, and colony formation for each condition calculated in relation to values obtained for untreated control cells.
Statistical analysis
For analysis of apoptosis and DC m , and clonogenic assays, values represent the means7s.d. for at least three separate experiments performed in triplicate. The significance of differences between experimental variables was determined using the Student's t-test. Analysis of synergism was performed according to median-dose effect analysis (Chou and Talalay, 1984 ) using a commercially available software program (Biosoft, Ferguson, MO, USA).
